Leiomyosarcoma: Current Clinical Management and Future Horizons.

Surg Oncol Clin N Am

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Division of General Surgery, Sinai Health System, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Published: July 2022

Leiomyosarcomas are soft tissue tumors that are derived from smooth muscle mainly in the pelvis and retroperitoneum. Percutaneous biopsy is paramount to confirm diagnosis. Imaging is necessary to complete clinical staging. Multimodal treatment should be directed by expert sarcoma multidisciplinary teams that see a critical volume of these rare tumors. Surgery is the mainstay of curative intent treatment; however due to its high metastatic progression, there may be a benefit for neoadjuvant systemic treatment. Adjuvant systemic treatment has no proven disease-free survival, and its main role is in the palliative setting to potentially prolong overall survival.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2022.03.011DOI Listing

Publication Analysis

Top Keywords

systemic treatment
8
leiomyosarcoma current
4
current clinical
4
clinical management
4
management future
4
future horizons
4
horizons leiomyosarcomas
4
leiomyosarcomas soft
4
soft tissue
4
tissue tumors
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!